Author

Meg Carini

Observed name: M. Carini

Observed institution: Agenus (United States)

OpenAlex ID: A5014568848

VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection

2023 · Thomas Louie, Yoav Golan, et al. · JAMA · 206

Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors

2018 · J. Coward, C. Lemech, et al. · Annals of Oncology · 3

Abstract CT104: Evaluation of peripheral T cell subset proliferation as a pharmacodynamic assay to guide the development of anti-CTLA-4 and PD-1 antibody combinations in patients with solid tumors

2018 · Paul De Souza, Agnieszka Malczewski, et al. · Cancer Research · 3

109: an 8-strain, Rationally Defined Bacterial Consortium, Ve303, Reduces the Risk of Clostridioides Difficile Infection (cdi) Recurrence Compared With Placebo in Adults at High Risk for Recurrence: Results of the Phase 2 Consortium Study

2022 · Thomas J. Louie, Yoav Golan, et al. · Gastroenterology · 2

Works count: 4

Citation count: 213

H-index: 3

I10-index: 1